ANB032, an Investigational B and T Cell Lymphocyte Attenuator (BTLA) Checkpoint Receptor Agonist, Modulates Dendritic Cell (DC) Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis Pathophysiology
Muench et al., 2024
ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells
Luu et al., 2024
Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
Parmley et al., 2024
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Inhibits Peripheral T Cell Proliferation and Cytokine Secretion and Reduces Circulating PD-1 High Expressing CD4 and CD8 T Cells: Results from a Phase 1 Healthy Volunteer Clinical Trial
Luu et al., 2023
A Phase 2b, Randomized, Double Blind, Placebo Controlled, Global Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Moderate to Severe Atopic Dermatitis
Ehst et al., 2023
ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells: Results from a First-in-Human Phase 1 Study
Luu et al., 2023
Optimizing PD-1 Agonist Signaling with Membrane-Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody
Parmley et al., 2023
Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Demonstrated Modulation of Peripheral T Cell Activity and Reduction of Circulating PD-1 high Expressing CD4 and CD8 T Cells in a Phase 1 Healthy Volunteer Clinical Trial
Dahl et al., 2022
A Phase 2b, Randomized, Double Blind, Placebo Controlled, Multicenter, Global Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis
Silverberg et al., 2023
Discovery of a Novel High Affinity Anti-Human CD122 Antagonist Monoclonal Antibody (ANB033) that Abrogates IL-2 and IL-15 Signaling for the Treatment of T Cell-Mediated Inflammatory and Autoimmune Diseases
Hare et al., 2023
ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibited T Cell Proliferation, Reduced Inflammatory Cytokines, and Down Modulated BTLA Expression on Circulating T and B Cells in Phase 1, Progresses Into a Phase 2 Study in Atopic Dermatitis
Luu et al., 2023
ANB032, a Novel BTLA/HVEM Therapeutic Antibody, Inhibited T cells Derived from Atopic Dermatitis Patients In-vitro
Hsu et al., 2021
Soluble BTLA (sBTLA) is Induced Following Targeting of BTLA In-vivo by ANB032, a Novel BTLA/HVEM Modulator Therapeutic Antibody for the Treatment of Autoimmune Disease
Dahl et al., 2021
Identification and Characterization of TSR-042, a Novel Anti-PD-1 Therapeutic Antibody
Laken et al., 2016